Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuela Salvatorelli

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|November 19, 2024
Humans and Rodents: The Case of hOAT4 and mOat5Pierantonio Menna, Emanuela Salvatorelli
Chemotherapy|January 26, 2017
Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief OverviewPierantonio Menna, Emanuela Salvatorelli
Cardiovascular Toxicology|July 27, 2007
Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanesLuca Gianni, Emanuela Salvatorelli, Giorgio Minotti
Expert Opinion on Drug Safety|July 13, 2017
Cancer drugs and QT prolongation: weighing risk against benefitPierantonio Menna, Emanuela Salvatorelli, Giorgio Minotti
Chemical Research in Toxicology|July 16, 2016
Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond AnthracyclinesPierantonio Menna, Emanuela Salvatorelli, Giorgio Minotti
The Journal of Pharmacology and Experimental Therapeutics|May 1, 2007
Doxorubicin degradation in cardiomyocytesPierantonio Menna, Emanuela Salvatorelli, Giorgio Minotti
Future Cardiology|August 5, 2015
Managing anthracycline-induced cardiotoxicity: beginning with the end in mindEmanuela Salvatorelli, Pierantonio Menna, Giorgio Minotti
Chemical Research in Toxicology|December 4, 2009
Anthracycline degradation in cardiomyocytes: a journey to oxidative survivalPierantonio Menna, Emanuela Salvatorelli, Giorgio Minotti
Chemotherapy|March 24, 2017
Do You Know Pixantrone?Giorgio Minotti, Pierantonio Menna, Emanuela Salvatorelli
Chemical Research in Toxicology|April 29, 2009
4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytesPierantonio Menna, Emanuela Salvatorelli, Giorgio Minotti
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
The Journal of Pharmacology and Experimental Therapeutics|November 19, 2024
Humans and Rodents: The Case of hOAT4 and mOat5Pierantonio Menna, Emanuela Salvatorelli
Chemotherapy|January 26, 2017
Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief OverviewPierantonio Menna, Emanuela Salvatorelli
Cardiovascular Toxicology|July 27, 2007
Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanesLuca Gianni, Emanuela Salvatorelli, Giorgio Minotti
Expert Opinion on Drug Safety|July 13, 2017
Cancer drugs and QT prolongation: weighing risk against benefitPierantonio Menna, Emanuela Salvatorelli, Giorgio Minotti
Chemical Research in Toxicology|July 16, 2016
Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond AnthracyclinesPierantonio Menna, Emanuela Salvatorelli, Giorgio Minotti
The Journal of Pharmacology and Experimental Therapeutics|May 1, 2007
Doxorubicin degradation in cardiomyocytesPierantonio Menna, Emanuela Salvatorelli, Giorgio Minotti
Future Cardiology|August 5, 2015
Managing anthracycline-induced cardiotoxicity: beginning with the end in mindEmanuela Salvatorelli, Pierantonio Menna, Giorgio Minotti
Chemical Research in Toxicology|December 4, 2009
Anthracycline degradation in cardiomyocytes: a journey to oxidative survivalPierantonio Menna, Emanuela Salvatorelli, Giorgio Minotti
Chemotherapy|March 24, 2017
Do You Know Pixantrone?Giorgio Minotti, Pierantonio Menna, Emanuela Salvatorelli
Chemical Research in Toxicology|April 29, 2009
4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytesPierantonio Menna, Emanuela Salvatorelli, Giorgio Minotti
Pageof 6